---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-274871"
form_type: "8-K"
ticker: "IBRX"
cik: "0001326110"
company_name: "ImmunityBio, Inc."
filed_at: "2024-12-11T23:59:59+00:00"
generated_at: "2026-05-29T04:38:26.133842+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# ImmunityBio prices $100M public offering at $3/sh and restructures $505M Nant Capital note

## Summary
- Public offering of 33.3M shares at $3/sh for gross proceeds ~$100M; net to company ~$93.1M from firm shares.
- Underwriters have 30-day option to purchase additional 5M shares at $3/sh; potential net proceeds $107.2M.
- Concurrent debt restructuring: Nant Capital notes consolidated into $505M note due Dec 2027, interest SOFR+8%, convertible at $5.427/sh.
- Limited consent from Oberland Capital (RIPA) obtained for the debt restructuring.
- Net proceeds intended for ANKTIVA commercialization, BCG-naïve NMIBC and NSCLC trials, R&D, working capital.

## SEC filing metadata
- accession: 0001193125-24-274871
- form_type: 8-K
- ticker: IBRX
- cik: 0001326110
- company_name: ImmunityBio, Inc.
- filed_at: 2024-12-11T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1326110/000119312524274871/0001193125-24-274871-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1326110/000119312524274871/d875134d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-274871
- JSON: https://secwatch.observer/filing/0001193125-24-274871.json
- Plain text: https://secwatch.observer/filing/0001193125-24-274871.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.